Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Products under Development by Stage of Development | 8 | 1 |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Products under Development by Therapy Area | 9 | 1 |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Products under Development by Indication | 10 | 1 |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Products under Development by Companies | 13 | 2 |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Therapeutics Assessment | 15 | 6 |
| Assessment by Monotherapy/Combination Products | 15 | 1 |
| Assessment by Mechanism of Action | 16 | 1 |
| Assessment by Route of Administration | 17 | 2 |
| Assessment by Molecule Type | 19 | 2 |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Companies Involved in Therapeutics Development | 21 | 9 |
| AbbVie Inc | 21 | 1 |
| Abeome Corporation | 22 | 1 |
| Affibody AB | 23 | 1 |
| Cell Medica Limited | 24 | 1 |
| Eli Lilly and Company | 25 | 1 |
| Johnson &Johnson | 26 | 1 |
| Merck KGaA | 27 | 1 |
| Novartis AG | 28 | 1 |
| Orega Biotech SAS | 29 | 1 |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Drug Profiles | 30 | 30 |
| ABT-122 Drug Profile | 30 | 2 |
| ABY-035 Drug Profile | 32 | 1 |
| CNTO-6785 Drug Profile | 33 | 2 |
| DLX-2882 Drug Profile | 35 | 1 |
| DLX-2907 Drug Profile | 36 | 1 |
| DLX-2909 Drug Profile | 37 | 1 |
| ixekizumab Drug Profile | 38 | 6 |
| M-1095 Drug Profile | 44 | 1 |
| Monoclonal Antibody to Inhibit IL-17A for Psoriasis and Inflammation Drug Profile | 45 | 1 |
| OREG-203 Drug Profile | 46 | 1 |
| secukinumab Drug Profile | 47 | 13 |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Dormant Projects | 60 | 1 |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Discontinued Products | 61 | 1 |
| Interleukin 17A (Cytotoxic T Lymphocyte Associated Antigen 8 or CTLA8 or IL17A) Featured News &Press Releases | 62 | 13 |
| Aug 04, 2016: NICE draft guidance recommends new drug for people with ankylosing spondylitis | 62 | 1 |
| Jun 21, 2016: Health Canada approval of Taltz (ixekizumab) Brings Targeted Therapy to Canadians Living with Moderate-to-Severe Plaque Psoriasis | 62 | 2 |
| Jun 09, 2016: New drug clears psoriasis in clinical trials | 64 | 1 |
| Jun 08, 2016: Studies Demonstrate Lilly's Taltz (Ixekizumab) Maintained Or Achieved High Levels Of Skin Clearance For Patients With Moderate-To-Severe Plaque Psoriasis Through 60 Weeks: Results Published In The New England Journal Of Medicine | 65 | 1 |
| Jun 08, 2016: Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016 | 66 | 1 |
| Jun 07, 2016: Eli Lilly and Company Announces Data on Ixekizumab At Annual European Congress Of Rheumatology | 67 | 1 |
| Jun 07, 2016: Tampa Dermatologist Launches Clinical Trial for Psoriatic Arthritis Patients | 68 | 1 |
| Jun 02, 2016: AbbVie Announces Presentation on ABT-122 at the Annual European Congress of Rheumatology | 68 | 1 |
| May 04, 2016: Affibody Announces Initial Results from a Phase I Study of ABY-035 | 69 | 1 |
| May 02, 2016: Lilly's Taltz (Ixekizumab) Now Available In The U.S. For The Treatment Of Moderate-To-Severe Plaque Psoriasis | 69 | 2 |
| Apr 27, 2016: COSENTYX - first Interleukin-17A inhibitor for psoriatic arthritis and ankylosing spondylitis approved by Health Canada | 71 | 1 |
| Apr 26, 2016: Lilly announces European Commission approval for plaque psoriasis drug | 71 | 1 |
| Apr 23, 2016: OptiMed Specialty Pharmacy to Distribute Cosentyx | 72 | 1 |
| Apr 05, 2016: Diplomat Announces TALTZ Availability for the Treatment of Plaque Psoriasis | 72 | 1 |
| Mar 22, 2016: Lilly's Taltz (Ixekizumab) Receives U.S. FDA Approval For The Treatment Of Moderate-To-Severe Plaque Psoriasis | 73 | 2 |
| Appendix | 75 | 2 |
| Methodology | 75 | 1 |
| Coverage | 75 | 1 |
| Secondary Research | 75 | 1 |
| Primary Research | 75 | 1 |
| Expert Panel Validation | 75 | 1 |
| Contact Us | 75 | 1 |
| Disclaimer | 76 | 1 |